Healthcare | October 31, 2025
Lupin Digital Health launches VITALYFE
AI-powered cardiometabolic wellness platform for India’s workforce
AI-powered cardiometabolic wellness platform for India’s workforce
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Subscribe To Our Newsletter & Stay Updated
